The article weighs whether AI-designed miniproteins could complement antibodies as therapeutic binders. Their small size, stability, and computational designability are advantages, while pharmacokinetics and immunogenicity remain important considerations.
Potential use cases include binding sites that are difficult for full-sized antibodies to reach, such as intracellular targets, and radiopharmaceutical delivery where rapid renal clearance can be useful. Fc fusion may extend half-life, though that can reduce the distinction from antibody formats.
The post points to experimental binder results from BindCraft and RFdiffusion-based pipelines, with structure prediction and sequence-design tools used together to prioritize candidates. It presents miniproteins as a promising modality with specific trade-offs rather than a wholesale replacement for antibodies.